Table 1 Characteristics of included studies
Study | Sample size (E/C) | Experimental groups (CYC/GCs) | Cumulative CYC/GCs dose | Control groups | Treatment for the thyroid disorder | Treatment duration | Number of patients with response (E/C) | Criteria for response |
|---|---|---|---|---|---|---|---|---|
Shi 2004 [25] | 53/52 | CYC/DEX | 0.1 g/0.05 g | GCs (DEX) | ATD | 10 weeks | 29/25 | Reduction of proptosis ≥ 2mm |
Liu 2005 [26] | 30/30 | CYC/MPS | 1.2 g/3 g | GCs (MPS) | ATD | 1 month | 29/24 | Decline of CAS ≥ 2 |
Zhang 2005 [22] | 30/30 | CYC/MPS | 2.4 g/6 g | Negative control | ATD | 1 month | 30/2 | Reduction of proptosis > 2mm |
Ruan 2006 [27] | 54/51 | CYC/DEX | 0.5 g/0.05 g | GCs (DEX) | ATD | 10 weeks | 35/30 | Reduction of proptosis > 2mm |
Tang 2006 [28] | 30/27 | CYC/P | 1.6 g/0.96 g | GCs (P) | ATD | 1 month | 29/11 | Reduction of proptosis > 2mm |
Su 2014 [29] | 24/24 | CYC/MPS | NA/NA | Negative control | Thiamazole | NA | 23/19 | NA |
Dai 2015 [30] | 22/22 | CYC/MPS | 6 g/3 g | GCs (P) | ATD | 3 months | 19/14 | Reduction of proptosis ≥ 2mm |
Wang 2015 [31] | 40/40 | CYC/P | 4.48 g/1.16 g | Negative control | ATD | 4 months | 36/19 | Reduction of proptosis ≥ 2mm |
Wen 2016 [32] | 46/46 | CYC/MPS | 1.8 g/4.5 g | Negative control | ATD/Levothyroxine | 3 weeks | 40/32 | Reduction of proptosis ≥ 2mm and decline of CAS ≥ 2 |
Gao 2018 [33] | 29/29 | CYC/MPS | 1.8g/4.5 g | Negative control | ATD/Levothyroxine | 3 weeks | 25/18 | Reduction of proptosis ≥ 2mm and decline of CAS ≥ 2 |
Liang 2020 [34] | 40/39 | CYC/MPS | 3 g/0.96 g | GCs (MPS) | ATD | 3 months | 39/31 | NA |
Cajal 2020 [35] | 40/40 | CYC/MPS | 2.7g/5.4 g | GCs (MPS) | ATD | 3 months | 38/31 | NA |
Wang 2021 [36] | 34/30 | CYC/P | 5.6 g/2.73 g | Negative control | Thiamazole | 3 months | 31/23 | Reduction of proptosis > 2mm |